Last reviewed · How we verify
Placebo of TQC2731
Placebo of TQC2731 is a Small molecule drug developed by Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.. It is currently in Phase 3 development.
This is a placebo control arm and contains no active pharmaceutical ingredient.
At a glance
| Generic name | Placebo of TQC2731 |
|---|---|
| Sponsor | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
As a placebo, this formulation is pharmacologically inert and serves as a control comparator in the phase 3 clinical trial of TQC2731. It allows for assessment of the true efficacy and safety of the active drug by comparison against a non-active treatment.
Approved indications
Common side effects
Key clinical trials
- Clinical Trial of TQC2731 Injection in Patients With Chronic Sinusitis and Nasal Polyps (PHASE3)
- A Clinical Study of TQC2731 Injection in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (PHASE2)
- Evaluate the Efficacy and Safety of TQC2731 Injection in Patients With Severe Asthma. (PHASE2)
- A Clinical Study of TQC2731 Injection in the Treatment of Chronic Rhinosinusitis With Nasal Polyps (PHASE2)
- TQC2731 Clinical Trial for the Treatment of Severe Asthma With Injection (PHASE3)
- Phase I Clinical Trial of TQC2731 Injection (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo of TQC2731 CI brief — competitive landscape report
- Placebo of TQC2731 updates RSS · CI watch RSS
- Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. portfolio CI